Completely non sense.
How would a maintenance drug to usw Nw4 or above for testing if it merely maintains, and you don't even read the article which clearly says that has increase in hair count and density.
Sm04554
Collapse
X
-
For maintenance. Forget regrowth. In Greece some users reported positive results with VPA. Which is available already with similar mechanism as sm0
I wonder how would sm0 compare with VPA. Are they equal strength?Leave a comment:
-
Duece. We should know more hopefully in jan when phase 2 wraps up. If it retains hair thats a huuuuge plusLeave a comment:
-
If that 21st century cures act passes couldnt they skip phase 3?
Also, shouldnt that act be getting the yay or nay anyday now?Leave a comment:
-
-
If that 21st century cures act passes couldnt they skip phase 3?
Also, shouldnt that act be getting the yay or nay anyday now?Leave a comment:
-
Do SM and Bim work on different stages of whatever the chain of processes is that causes follicles to go bad though?Leave a comment:
-
I think Bimatoprost is almost done.
If SM significantly outperforms Minox in trials, the chances of seeing another growth stim will diminish considerably.
I still hope CB comes to the market. A receptor antagonist is always welcomeLeave a comment:
-
The findings are consistent with preclinical in vivo animal models, in which SM04554 has been shown to generate new hair follicles and increase hair count.
Looks like we're getting incredibly close to a new product hitting the market.
BIM, SM and Histogen all showing a high amount of efficacy in phase 2+ trials.
very exciting times! Hopefully SM goes straight to phase III now, very unlikely it fails as they've already proven safety and just need to show widespread efficacy.
On top of that, they seem very happy with this product, already talking about releasing results at the next conference(while BIM was more hush-hush when they didnt quite get amazing results).Leave a comment:
-
Wikipedia summarizes nicely:
"Phase III[edit]
This phase is designed to assess the effectiveness of the new intervention and, thereby, its value in clinical practice.[1] The percentage of Phase II trials that proceed to Phase III, as of 2008, is 18%.[6] Phase III studies are randomized controlled multicenter trials on large patient groups (300–3,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how effective the drug is, in comparison with current 'gold standard' treatment. Because of their size and comparatively long duration, Phase III trials are the most expensive, time-consuming and difficult trials to design and run, especially in therapies for chronic medical conditions. Phase III trials of chronic conditions or diseases often have a short follow-up period for evaluation, relative to the period of time the intervention might be used in practice.[1] This is sometimes called the "pre-marketing phase" because it actually measures consumer response to the drug."Leave a comment:
-
Leave a comment:
-
I really do not remember the source, but I saw it from a website and one member mentioned that the easiest phase is phase 1 and the most difficult one is phase 3Leave a comment:
Leave a comment: